COVID-19 (Coronavirus)


Condition: COVID-19


Key Inclusion Criteria:

  • Currently not hospitalized
  • 18-65 years old
  • Has one or more mild or moderate COVID-19 symptoms

Key Exclusion Criteria:

  • Hospitalization
  • BMI ≥35
  • SpO2 ≤93% on room air at sea level or PaO2/FiO2 <300, respiratory rate ≥30 per minute, heart rate ≥125 per minute

Study Name:

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4) (IRB no. 00001143)


The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called LY3819253, alone and in combination with the drug LY3832479, in individuals with mild to moderate COVID-19. Researchers also aim to determine the dosage of these drugs that should be given. Participants have a 1 in 5 chance of receiving a placebo (inactive substance) and a 4 in 5 chance of receiving LY3819253 or combination of LY3819253 and LY3832479. Because the COVID-19 pandemic may impact participants’ ability or willingness to attend onsite study visits, mobile health visits will be offered to provide the required study assessments.

Principal Investigator

Pulmonary Research Team